{"organizations": [], "uuid": "8d38fb5ae7349669418560913ade978e9a1f2d97", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/14/globe-newswire-edap-tms-sa-edap-reports-2018-first-quarter-results.html", "country": "US", "domain_rank": 767, "title": "EDAP TMS SA : EDAP Reports 2018 First Quarter Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.454, "site_type": "news", "published": "2018-05-15T01:00:00.000+03:00", "replies_count": 0, "uuid": "8d38fb5ae7349669418560913ade978e9a1f2d97"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/14/globe-newswire-edap-tms-sa-edap-reports-2018-first-quarter-results.html", "ord_in_thread": 0, "title": "EDAP TMS SA : EDAP Reports 2018 First Quarter Results", "locations": [], "entities": {"persons": [{"name": "marc oczachowski", "sentiment": "none"}], "locations": [{"name": "san francisco", "sentiment": "none"}, {"name": "france", "sentiment": "none"}, {"name": "lyon", "sentiment": "none"}], "organizations": [{"name": "edap tms sa", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "american urological association", "sentiment": "none"}, {"name": "tms sa", "sentiment": "none"}, {"name": "edap", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "2018 Q1 total revenue records a 6% increase year-over-year Focal One Final Additional Information submitted to FDA early May EDAP to attend American Urological Association congress in San Francisco, May 18-21, 2018\nLYON, France, May 14, 2018 -- EDAP TMS SA (Nasdaq: EDAP) (\"the Company\"), the global leader in therapeutic ultrasound, announced today financial results for the first quarter of 2018, and provided an update on strategic and operational developments.\nMarc Oczachowski, EDAP's Chief Executive Officer, said: \"We are pleased with the return to growth in the first quarter, a trend we expect to sustain, and we look forward to feedback from the FDA following our submission for Focal One to the Agency. We also look forward to engaging with our customers and key opinion leaders at the upcoming annual meeting of the American Urological Association later this month where we will showcase the important benefits of Focal One for soft tissue ablation of the prostate.\"\nFirst Quarter 2018 Results\nTotal revenue for the first quarter 2018 was EUR 9.2 million (USD 11.3 million), a 6% increase compared to EUR 8.7 million (USD 9.3 million) for the first quarter of 2017.\nTotal revenue in the HIFU business for the first quarter 2018 was EUR 2.4 million (USD 3.0 million), a 5% increase compared to EUR 2.3 million (USD 2.5 million) for the first quarter of 2017.\nFor the three months ended March 31, 2018, total revenue for the Lithotripsy division was EUR 6.7 (USD 8.3 million), a 6% increase compared to EUR 6.4 million (USD 6.8 million) during the year-ago period.\nGross profit for the first quarter 2018 was EUR 4.0 million (USD 4.9 million), compared to EUR 3.6 million (USD 3.8 million) for the year-ago period. Gross profit margin on net sales was 43.8% in the first quarter of 2018, compared to 41.1% in the year-ago period.\nOperating expenses were EUR 4.4 million (USD 5.4 million) for the first quarter of 2018, compared to EUR 4.0 million (USD 4.3 million) for the same period in 2017.\nOperating loss for the first quarter 2018 was EUR 0.4 million (USD 0.5 million), compared to an operating loss of EUR 0.4 million (USD 0.4 million) in the first quarter of 2017.\nNet income for the first quarter 2018 was EUR 89 thousand (USD 109 thousand), or earnings of EUR 0.00 per diluted share, as compared to a net income of EUR 1.7 million (USD 1.8 million), or earnings of EUR 0.06 per diluted share in the year-ago period. Net income in the first quarter of 2018 included non-cash interest expense of EUR 647 thousand (USD 797 thousand) to adjust the accounting fair value of the outstanding warrants.\nConference Call\nAn accompanying conference call will be conducted by Philippe Chauveau, Chairman of the Board; Marc Oczachowski, Chief Executive Officer; and François Dietsch, Chief Financial Officer, to review the results. The call will be held at 8:30 AM ET, on Tuesday May 15, 2018. Please refer to the information below for conference call dial-in information and webcast registration.\nConference Call & Webcast\nTuesday, May 15, 2018 @ 8:30am Eastern Time\nDomestic: 866-548-4713\nInternational 323-794-2093\nPasscode: 9225280\nWebcast: http://public.viavid.com/index.php?id=129164\nReplays, Available through May 29, 2018:\nDomestic: 844-512-2921\nInternational: 412-317-6671\nReplay PIN: 9225280\nFollowing the live call, a replay will be available on the Company's website, www.edap-tms.com under \"Investors Information.\"\nAbout EDAP TMS SA\nA recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® (currently pending FDA clearance) in 2013 as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com , and us.hifu-prostate.com.\nForward-Looking Statements\nIn addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections \"Cautionary Statement on Forward-Looking Information\" and \"Risk Factors\" in the Company's Annual Report on Form 20-F.\nCompany Contact\nBlandine Confort\nInvestor Relations / Legal Affairs\nEDAP TMS SA\n+33 4 72 15 31 50\nbconfort@edap-tms.com\nInvestor Contact\nJeremy Feffer\nLifeSci Advisors, LLC\n212-915-2568\njeremy@lifesciadvisors.com\nEDAP TMS S.A.\nUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\n(Amounts in thousands of Euros and U.S. Dollars, except per share data)\nThree Months Ended: Three Months Ended:\nMarch 31,\n2018\nEuros March 31,\n2017\nEuros March 31,\n2018\n$US March 31,\n2017\n$US Sales of medical equipment\nNet Sales of RPP and Leases 5,751\n1,210 5,512\n1,295 7,085\n1,491 5,899\n1,386 Sales of spare parts, supplies and\nServices\n2,197\n1,842\n2,707\n1,972 TOTAL NET SALES 9,158 8,648 11,283 9,257 Other revenues - 26 - 28 TOTAL REVENUES 9,158 8,675 11,283 9,285 Cost of sales (5,147) (5,123) (6,341) (5,483) GROSS PROFIT 4,011 3,551 4,942 3,801 Research & development expenses (1,000) (896) (1,232) (959) S, G & A expenses (3,413) (3,075) (4,205) (3,291) Total operating expenses (4.413) (3,971) (5,437) (4,250) OPERATING PROFIT (LOSS) (402) (419) (495) (449) Interest (expense) income, net 639 1,983 787 2,123 Currency exchange gains (loss), net (15) 175 (18) 188 INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST 223 1,739 274 1,861 Income tax (expense) credit (134) (58) (165) (62) NET INCOME (LOSS)\n89 1,681 109\n1,799 Earning per share - Basic 0.00 0.06 0.00 0.06 Average number of shares used in computation of EPS 28,997,866 28,839,099 28,997,866 28,839,099 Earning per share - Diluted 0.00 0.06 0.00 0.06 Average number of shares used in computation of EPS for positive net income\n29,345,366 30,213,544 29,345,366 30,213,544 NOTE: Translated for convenience of the reader to U.S. dollars at the 2018 average three months' noon buying rate of 1 Euro = 1.2320 USD, and 2017 average three months noon buying rate of 1 Euro = 1.0703 USD.\nEDAP TMS S.A.\nUNAUDITED CONSOLIDATED BALANCE SHEETS HIGHLIGHTS\n(Amounts in thousands of Euros and U.S. Dollars)\nMar. 31,\n2018\nEuros Dec. 31,\n2017\nEuros Mar. 31,\n2018\n$US Dec. 31,\n2017\n$US\nCash, cash equivalents and short term investments 18,142 20,004 22,351 24,049 Total current assets 37,734 39,558 46,487 47,557 Total current liabilities 13,843 16,134 17,054 19,397 Shareholders' Equity 25,439 25,143 31,340 30,227 NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.2320 USD, on March 31, 2018 and at the noon buying rate of 1 Euro = 1.2022 USD, on December 31, 2017.\nEDAP TMS S.A.\nUNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION\nTHREE MONTHS ENDED MARCH 31, 2018\n(Amounts in thousands of Euros)\nHIFU Division\nUDS Division\nCorporate Total After Consolidation\nSales of goods\n1,109\n4,642\n5,751 Sales of RPPs & Leases 861 349 1,210 Sales of spare parts & services 467 1,730 2,197 TOTAL NET SALES\n2,437 6,721 9,158 Other revenues\n- - - TOTAL REVENUES 2,437 6,721 9,158 GROSS PROFIT\n(% of Total Revenues) 1,310 53.7% 2,702 40.2% 4,011 43.8%\nResearch & Development\n(611) (389) (1,000) Total SG&A plus depreciation (1,381) (1,696) (336) (3,413)\nOPERATING PROFIT (LOSS)\n(682)\n616\n(336)\n(402)\nSource:EDAP TMS S.A.", "external_links": ["https://www.globenewswire.com/Tracker?data=vIl1ie5m6W5CGZfYtDLD2W232mUDqDTeMC_KOi2AElDpUouZ4uQ3ceqYMiFSpMCLHce57oTmSpSP6QPTZBxSgeRla4rZXDmiKd1DFjhBUqo=", "https://www.globenewswire.com/Tracker?data=veSbbNuTxduMaHhCrCjQ3ZfblskT_EgjjDcg1NPk7h8QP1hOWpMsyZ11l1qeNWf7QcX856HO-_1ifGGKZA7n8LYPzJawXW2FGkqPvNZ2XQyojUSy3GP_C1adAl0JsJ_w", "https://www.globenewswire.com/Tracker?data=mGz2CnlXzbhet5pZNZfXXWmXWaxHahmzMhpVElEDBAVXFsOSc8jcCWWa1HCE32xMUAcLqMT7qvAuIuFKAWPI1z4jX202tRcT_knOCdVqjAUWaE0RPb9UGI52Q2CCzy8gAy9nopz48WYihaQraJtv2Q==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/57f884b2-d97a-4f50-b678-d47c38bc8e39", "https://www.globenewswire.com/Tracker?data=N_khhYYIo54hKwRmE7suB93lSbb0oo3vT6cmU4EtzvlqU9sENx_qm6-RPR-JMuPI9Jxio9Q9a9e-OKey_pZdAmifn2zmXel-taBJFLgiMcQ=", "http://public.viavid.com/index.php?id=129164", "https://www.globenewswire.com/Tracker?data=mGz2CnlXzbhet5pZNZfXXVz65QRLJJ19rf1LABHdazp1wWnAC-E_yu9xaR0HDqk9svc4oLXnGP2JFeegrOFFa0qjISPsom3MIWEYH3rbqfQ=", "https://www.globenewswire.com/Tracker?data=rsmG0P_vxFEDY3NCEzfJTtmvzzo6cfjFlXZwsMeOLZ29floU2r7rsyeQNsBpz269xwlNJ8fZPn88e--WJRGOHyDMuwQ-bro6fxrfUatElqj9iUssqbia_-LlxW9izSXx"], "published": "2018-05-15T01:00:00.000+03:00", "crawled": "2018-05-15T01:49:50.080+03:00", "highlightTitle": ""}